Man Starts Campaign Seeking Health Warnings On Smoking Cessation Products
Date: 4th June 2009
As soon as Matthew Fairweather came to know that a quit smoking drug, made available as champix in Australia, led to specific neurological side-effects and poisonous caffeine blood levels among smokers using high-caffeine, he initiated a door-to-door campaign in the Peninsula streets and urged for warning labels to be included in products meant for facilitating smoking cessation.
According to Matthew Fairweather, after undertaking a thorough research, he got in touch with specific reports on Champix leading to deaths and heart attacks in the US as well as in UK and thereafter started the campaign demanding health warnings on anti-smoking products. He adds that as he got to know the reports on deaths and heart attacks caused by Champix in relation to coffee drinking and heavy caffeine intake, he abruptly stopped taking the anti-smoking medication.
Matthew Fairweather states that champix; the prescription-based quit smoking medication is known as chantix in US and is duly registered on the Pharmaceutical Benefits Scheme. He also makes it apparent that though champix is a medically approved drug, no warnings are displayed regarding the side-effects of caffeine use.
The campaigner Mr Fairweather further clarifies that chantix (champix) maker Pfizer Inc. has updated the chantix label in US pertaining to adverse neuro-psychiatric symptoms triggered off by the medicine but no warning labels are included in the Australian packaging of chantix. According to him, though his wife as well as father-in-law had considerably decreased their smoking addiction with the help of champix, he would definitely go-ahead with the campaign and is also prepared to walk to Canberra in order to achieve his objective.
Source: http://redcliffe-and-bayside-herald.whereilive.com.au/ |
